Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Return on Equity data on record, last reported at 0.0% in Q1 2026.

  • On a quarterly basis, Return on Equity changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Equity reached 0.0% in Q1 2026 per IKT's latest filing, up from 0.0% in the prior quarter.
  • Over the last five years, Return on Equity for IKT hit a ceiling of 0.0% in Q1 2026 and a floor of 0.09% in Q3 2024.
  • A 5-year average of 0.01% and a median of 0.01% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: dropped -8bps in 2024, then rose 8bps in 2025.
  • Tracing IKT's Return on Equity over 5 years: stood at 0.01% in 2022, then tumbled by -97bps to 0.02% in 2023, then soared by 61bps to 0.01% in 2024, then skyrocketed by 30bps to 0.0% in 2025, then rose by 23bps to 0.0% in 2026.
  • Business Quant data shows Return on Equity for IKT at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.01% in Q3 2025.